• Milestone Pharma
    Milestone Pharma
    • About Us
      • Leadership Team
      • Board of Directors
      • Careers
    • Areas of Focus
      • Paroxysmal supraventricular tachycardia (PSVT)
      • Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
      • Other Therapeutic Applications
    • Research & Development
      • Etripamil
      • Publications
      • Clinical Trials
      • Patient Access
    • Investors & Media
      • News & Events
      • Stock Information
      • Financial Information
      • Corporate Governance
      • Investor Resources
Milestone Pharma
Close
0
  • Milestone Pharma

Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 Study

  • May 4, 2022
  • Publication
  • By Sub-editor
  • 0 Comments
0
  • Milestone Pharma

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Intranasal Etripamil, a Short-Acting Calcium Channel Blocker, in Healthy Japanese and non-Japanese Adults

  • April 4, 2022
  • Publication
  • By Sub-editor
  • 0 Comments

Careers | Contact Us | Privacy Policy | Terms of Use
© 2019 Milestone Pharmaceuticals USA, Inc. All Rights Reserved.
  • English: United States
    • English: Canada
    • Français (French): Canada

Our website content is tailored by geographical region to comply with local regulatory requirements. Please select which country’s site you’d like to visit.

  • English: United States
  • English: Canada
  • Français (French): Canada